Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
NCT06252675Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jun 2024
- Primary completion
- Jul 2028
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab, pirtobrutinib in mantle cell lymphoma (MCL), sponsored by University of California, San Francisco. Started Jun 2024; status: recruiting.
02
Drugs
glofitamabpirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06252675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252675.